What is the anti-CD47 drugs?

What is the anti-CD47 drugs?

Upon administration, anti-CD47 monoclonal antibody CC-90002 selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells….anti-CD47 monoclonal antibody CC-90002.

Is Magrolimab FDA approved?

Magrolimab is an investigational product and is not approved by any regulatory authority for any use; its safety and efficacy have not been established.

Who manufactures Magrolimab?

About Ono and Gilead Collaboration (which became a wholly owned subsidiary of Gilead in April 2020) to exclusively develop, manufacture and commercialize 5F9 (magrolimab), their monoclonal antibody against CD47, in Japan, South Korea, Taiwan and ASEAN countries.

What is Magrolimab?

A humanized monoclonal antibody targeting the human cell surface antigen CD47, with potential immunostimulating and antineoplastic activities.

What is the function of CD47?

CD47, or integrin-associated protein, is a cell surface ligand expressed in low levels by nearly all cells of the body. It plays an integral role in various immune responses as well as autoimmunity, by sending a potent “don’t eat me” signal to prevent phagocytosis.

Is CD47 a gene?

CD47 Gene – CD47 Molecule This gene encodes a membrane protein, which is involved in the increase in intracellular calcium concentration that occurs upon cell adhesion to extracellular matrix.

What is Magrolimab used for?

Magrolimab is a drug that targets a protein on the surface of tumor cells called CD47 and allows specialized immune cells, called macrophages, to destroy the tumor cells.

Is CD47 an immune checkpoint?

CD47 is a novel macrophage immune checkpoint that plays a broad role in cancer immune evasion across multiple cancer types and particularly in myeloid malignancies. In addition, CD47 has been identified as an LSC marker in AML.

Does CD47 have a role in cancer?

The clinical trial builds upon previous studies of CD47 and its role in cancer that were conducted in Weissman’s laboratory and funded by the California Institute of Regenerative Medicine and the Ludwig Institute for Cancer Research.

Is anti-CD47 cancer therapy safe?

Anti-CD47 cancer therapy safe, shows promise in small clinical trial An immunotherapy conceived at Stanford appeared safe in an early clinical trial. Half of the participants responded positively to the treatment, aimed at triggering macrophages to engulf cancer cells, the researchers reported. Oct 31 2018

Is CD47 an adverse prognostic factor in acute myeloid leukemia?

[9] Majeti R, Chao MP, Alizadeh AA et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell2009; 138:286–299. [PMC free article][PubMed] [Google Scholar] [10] Liu X, Kwon H, Li Z, Fu YX. Is CD47 an innate immune checkpoint for tumor evasion? J. Hematol. Oncol2017; 10:12.

Is the cd47-signal regulatory protein alpha interaction a target for solid tumors?

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad. Sci. U.